OBI 3424
Alternative Names: AST-3424; OBI-3424; TH-3424Latest Information Update: 17 Oct 2024
Price :
$50 *
At a glance
- Originator Threshold Pharmaceuticals
- Developer Ascentawits Pharmaceuticals; National Cancer Institute (USA); OBI Pharma
- Class Antineoplastics; Aziridines; Benzamides; Benzene derivatives; Ethers; Nitro compounds; Phosphorus compounds; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
- Phase I/II Liver cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 27 Sep 2024 Efficacy data from a phase I/II trial in Liver cancer released by Ascentawits Pharma
- 18 Jun 2024 Chemical structure information added
- 31 May 2024 Efficacy, adverse event and pharmacokinetics data from a phase I/II trial in Solid tumour presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)